Horio Y - Search Results

1

Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis.

Tanaka K, Osada H, Murakami-Tonami Y, Horio Y, Hida T, Sekido Y. Tanaka K, et al. Among authors: horio y. Cancer Lett. 2017 Jan 28;385:215-224. doi: 10.1016/j.canlet.2016.10.020. Epub 2016 Oct 20. Cancer Lett. 2017. PMID: 27773750

2

Synergistic effects of adenovirus expressing wild-type p53 on chemosensitivity of non-small cell lung cancer cells.

Horio Y, Hasegawa Y, Sekido Y, Takahashi M, Roth JA, Shimokata K. Horio Y, et al. Cancer Gene Ther. 2000 Apr;7(4):537-44. doi: 10.1038/sj.cgt.7700148. Cancer Gene Ther. 2000. PMID: 10811471

3

Infrequent mutation of the hBUB1 and hBUBR1 genes in human lung cancer.

Sato M, Sekido Y, Horio Y, Takahashi M, Saito H, Minna JD, Shimokata K, Hasegawa Y. Sato M, et al. Among authors: horio y. Jpn J Cancer Res. 2000 May;91(5):504-9. doi: 10.1111/j.1349-7006.2000.tb00974.x. Jpn J Cancer Res. 2000. PMID: 10835495 Free PMC article.

4

Telomerase activation and p53 mutations in urethane-induced A/J mouse lung tumor development.

Ohno J, Horio Y, Sekido Y, Hasegawa Y, Takahashi M, Nishizawa J, Saito H, Ishikawa F, Shimokata K. Ohno J, et al. Among authors: horio y. Carcinogenesis. 2001 May;22(5):751-6. doi: 10.1093/carcin/22.5.751. Carcinogenesis. 2001. PMID: 11323394

5

Genetic alteration of the beta-catenin gene (CTNNB1) in human lung cancer and malignant mesothelioma and identification of a new 3p21.3 homozygous deletion.

Shigemitsu K, Sekido Y, Usami N, Mori S, Sato M, Horio Y, Hasegawa Y, Bader SA, Gazdar AF, Minna JD, Hida T, Yoshioka H, Imaizumi M, Ueda Y, Takahashi M, Shimokata K. Shigemitsu K, et al. Among authors: horio y. Oncogene. 2001 Jul 12;20(31):4249-57. doi: 10.1038/sj.onc.1204557. Oncogene. 2001. PMID: 11464291

6

Induction of antitumor immunity by transduction of CD40 ligand gene and interferon-gamma gene into lung cancer.

Noguchi M, Imaizumi K, Kawabe T, Wakayama H, Horio Y, Sekido Y, Hara T, Hashimoto N, Takahashi M, Shimokata K, Hasegawa Y. Noguchi M, et al. Among authors: horio y. Cancer Gene Ther. 2001 Jun;8(6):421-9. doi: 10.1038/sj.cgt.7700320. Cancer Gene Ther. 2001. PMID: 11498762

7

The expression of DNA methyltransferases and methyl-CpG-binding proteins is not associated with the methylation status of p14(ARF), p16(INK4a) and RASSF1A in human lung cancer cell lines.

Sato M, Horio Y, Sekido Y, Minna JD, Shimokata K, Hasegawa Y. Sato M, et al. Among authors: horio y. Oncogene. 2002 Jul 18;21(31):4822-9. doi: 10.1038/sj.onc.1205581. Oncogene. 2002. PMID: 12101420

8

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.

Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, Hatooka S, Shinoda M, Takahashi T, Yatabe Y. Mitsudomi T, et al. Among authors: horio y. J Clin Oncol. 2005 Apr 10;23(11):2513-20. doi: 10.1200/JCO.2005.00.992. Epub 2005 Feb 28. J Clin Oncol. 2005. PMID: 15738541 Clinical Trial.

9

Histone modification in the TGFbetaRII gene promoter and its significance for responsiveness to HDAC inhibitor in lung cancer cell lines.

Osada H, Tatematsu Y, Sugito N, Horio Y, Takahashi T. Osada H, et al. Among authors: horio y. Mol Carcinog. 2005 Dec;44(4):233-41. doi: 10.1002/mc.20135. Mol Carcinog. 2005. PMID: 16163707

10

ASH1 gene is a specific therapeutic target for lung cancers with neuroendocrine features.

Osada H, Tatematsu Y, Yatabe Y, Horio Y, Takahashi T. Osada H, et al. Among authors: horio y. Cancer Res. 2005 Dec 1;65(23):10680-5. doi: 10.1158/0008-5472.CAN-05-1404. Cancer Res. 2005. PMID: 16322211

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

375 results

Search Page